HD-OPM Archive
Topics › Kidney health

Lubiprostone preserved kidney function in a 118-patient phase II CKD trial

Gokhan Can · Aug 30, 2025 · ♥ 4 reactions · 2 comments · original Facebook post
Kidney healthGut microbiome
AI summary & key facts

A phase II trial in Science Advances found that the constipation drug lubiprostone (16 ug daily) preserved eGFR over 24 weeks versus decline on placebo. Surprisingly, it did not cut uremic toxins; instead it shifted the gut microbiome and raised spermidine. Kidney disease commonly accompanies heart disease.

Clinical trial shows constipation drug can treat patients with chronic kidney disease

A groundbreaking Phase II clinical trial published in Science Advances has revealed that the constipation drug lubiprostone can effectively treat chronic kidney disease (CKD) by preserving kidney function. In a 24-week study of 118 patients, those receiving a 16 µg daily dose of lubiprostone showed a significant preservation of their estimated glomerular filtration rate (eGFR) compared to a decline in the placebo group. The study's most surprising finding was the mechanism of action; contrary to the initial hypothesis, the drug did not reduce gut-derived uremic toxins. Instead, multiomics analysis showed that lubiprostone alters the gut microbiome, promoting the growth of beneficial bacteria that increase the production of the polyamine spermidine. This increase in circulating spermidine was shown in subsequent animal models to protect the kidneys by improving mitochondrial function and suppressing inflammation, establishing a novel and promising "gut-kidney axis" for future CKD therapies.

medicalxpress.comClinical trial constipation drug patientsChronic kidney disease (CKD) is a major health issue worldwide. Many patients end up requiring regular dialysis to avoid kidney failure and stay alive. Despite the severity of the condition, there are currently no drugs available that improve kidney function.medicalxpress.com

Research cited

#kidneys#egfr#microbiome#inflammation
← newer: Cumulative LDL-C thresholds: endothelial damage above 4000, older: Staying keto while still tracking ApoB and plaque markers (s →